DISEÑO ESTADISTICO DE ESTUDIOS CLINICOS EN FASE II Y SUS APLICACIONES EN CANCER DE MAMA: ACTUALIZACION DE UNA INVESTIGACION SOBRE LAS MODALIDADES DE EVALUACION Y COMUNICACION DE LA TOXICIDAD EN EL MISMO CONTEXTO CLINICO
Columnista Experta de SIIC Alessandro Ottaiano
en colaboración con
Massimo Di Maio, MD , National Cancer Institute; Ermelinda De Maio, MD , National Cancer Institute; Francesco Perrone, MD, PhD , National Cancer Institute
Fecha de aprobación: 25 de febrero, 2004
Primera edición en siicsalud:
26 de febrero, 2004
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/65744
Especialidad principal:
Oncología
Especialidades relacionadas:
Bioética,Bioquímica,Diagnóstico por Laboratorio,Farmacología,Medicina Interna,Medicina Legal,Obstetricia y Ginecología,Toxicología,
M.DiMaio, F.Perrone, C.Gallo, R.V.Iaffaioli, L.Manzione, F.Piantedosi, S.Cigolari, A.Illiano, S.Barbera, S.F.Robbiati, E.Piazza, G.P.Ianniello, L.Frontini, E.Veltri, F.Castiglione, F.Rosetti, E.DeMaio, P.Maione, C.Gridelli. Supportive care in patients with advanced non-small-cell lung cancer., . British Journal of Cancer. 89:1013-1021
C.Gridelli, C.Gallo, F.A.Shepherd, A.Illiano, F.V.Piantedosi, S.F.Robbiati, L.Manzione, S.Barbera, L.Frontini, E.Veltri, B.Findlay, S.Cigolari, R.Myers, G.P.Ianniello, V.Gebbia, G.Gasparini, S.Fava, V.Hirsh, A.Bezjak, L.Seymour and F.Perrone. Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer. A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada - Clinical Trials Group., Journal of Clinical Oncology. 21:3025-3034
G.Palmieri, P.A.Ascierto, F.Perrone, S.M.R.Satriano, A.Ottaiano, A.Daponte, M.Napolitano, C.Caracò, A.Cossu, C.Gallo, R.A.Satriano, G.Castello on behalf of the Melanoma Cooperative Group. Prognostic value of circulating melanoma cells detected by reverse transcriptase - polymerase chain reaction., Journal of Clinical Oncology. 15:767-773
C.Gridelli, F.Perrone, C.Gallo, S.Cigolari, A.Rossi, F.V.Piantedosi, S.Barbera, F.Ferraù, E.Piazza, F.Rosetti, M.Clerici, O.Bertetto, S.F.Robbiati, L.Frontini, C.Sacco, F.Castiglione, A.Favaretto, S.Novello, M.R.Migliorino, G.Gasparini, D.Galetta, R.V.Iaffaioli, V.Gebbia, on behalf of the MILES Investigators. Chemotherapy for elderly patients with advanced non-small cell lung cancer. The MILES (Multicenter Italian Lung cancer in the Elderly Study) phase 3 randomized trial., Journal of the National Cancer Institute. 95:362-372
A.deMatteis, F.Nuzzo, G.D'Aiuto, V.Labonia, G.Landi, E.Rossi, A.A.Mastro, G.Botti, E.DeMaio, F.Perrone. Docetaxel plus Epidoxorubicin as neoadjuvant treatment of large operable or locally advanced breast cancer., A single-center phase II study. Cancer. 15:895-901
F.Perrone, B.Daniele, G.B.Gaeta, S.Pignata, C.Gallo on behalf of the CLIP Investigators. Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma., Hepatology. 31:840-845
C.Gridelli, F.Perrone, C.Gallo on behalf of the ELVIS Investigators. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer., Journal of the National Cancer Institute. 91:66-72
C.Gallo, B.Daniele, G.B.Gaeta, F.Perrone, S.Pignata on behalf of the CLIP Investigators. Tamoxifen in the treatment of hepatocellular carcinoma: a multicenter randomized controlled trial., The Lancet, 352: 17-20, 1998. Letter: The Lancet, 352: 819-820, 1998. :
Alessandro Ottaiano
